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Introduction: Mesenchymal stem cells (MSCs) play a central role in the remediation of cell and tissue damage.
Erythropoietin (EPO) may enhance the beneficial influence of MSCs during recovery from tissue and organ injuries.
Microvesicles (MVs) released from MSCs contribute to the restoration of kidney damage. We studied the influence
of EPO on MVs derived from MSCs, and the protective effects of these factors in subjects with chronic kidney
disease (CKD).
Methods: The MVs derived from untreated MSCs (MSC-MVs) or from MSCs incubated in different concentrations of
EPO (1, 10, 100, and 500 IU/ml EPO-MVs) were used to treat renal injury of unilateral ureteral obstruction (UUO) in vivo,
and transforming growth factor-β1 (TGF-β1)-induced fibrosis in a human renal proximal tubular epithelial (HK2) cell line
in vitro. Western blot and reverse transcription polymerase chain reaction (RT-PCR) analyses were used to evaluate the
expression of epithelial and mesenchymal markers in the renal tissue and HK2 cells. Flow cytometry was used to assess
apoptosis within the HK2 cells, and microRNA (miRNA) microarray assays were used to determine the expression
profiles of miRNA in the MSC-MVs and EPO-MVs.
Results: Compared to MSC-MVs (untreated), there was a significant increase in the number of EPO-MVs derived
from MSCs treated with 1–100 IU/ml EPO, and these EPO-MVs had a greater benefit in UUO mice on days 7 and
14. Moreover, the EPO-MVs had a better restorative effect following TGF-β1-induced fibrosis in HK2 cells at 24 h
and 48 h. The flow cytometry results revealed that both types of MVs, especially EPO-MVs, play an important
anti-apoptotic role in HK2 cells treated with TGF-β1. The miRNA profiles of the MVs revealed that EPO-MVs
changed 212 miRNAs (fold-change ≥ 1.5), including miR-299, miR-499, miR-302, and miRNA-200, and that 70.28 % of
these changes involved upregulation. The changed miRNA in EPO-MVs may have contributed to their enhanced
protective effects following renal injury compared to MSC-MVs.
Conclusions: There was a dose-dependent increase in the level of EPO-MVs within the range of 1–100 IU/ml EPO.
Although both MSC-MVs and EPO-MVs protect the kidney from fibrosis-related damage, there is a superior effect
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Bone marrow-derived mesenchymal stem cells (MSCs),
also known as multipotent MSCs, offer a number of
potentially exciting effects for the treatment of chronic
kidney disease (CKD). Several in vitro studies have
suggested that MSCs may incorporate into the renal par-
enchyma, trans-differentiate into new renal tubular cells,
and then expand in a straightforward fashion [1–3].
However, in addition to the ability of MSCs to differenti-
ate in the kidney, the beneficial effects of these factors in
the cells of injured tissues have also been attributed to
their paracrine effects, which indirectly improve renal
function via the reduction of disease-related inflamma-
tion and fibrosis [4–6]. Accordingly, the paracrine effects
of MSCs have recently received more attention for their
potential therapeutic effects in CKD patients.
As a one-of-a-kind paracrine factor derived from
MSCs, microvesicles (MVs) have been described as a
new mode of cell-to-cell communication [7]. MVs inter-
act with target cells via surface-expressed ligands, and act
to transfer surface receptors and deliver proteins, messen-
ger RNA (mRNA), microRNA (miRNA), and bioactive
lipids. MVs that develop from bone-derived MSCs acceler-
ate recovery following acute kidney injury (AKI) induced
by toxic agents [8, 9] or ischemia–reperfusion [10], and in-
duce functional improvements in patients with CKD [11]
via miRNA- and mRNA-dependent mechanisms. Because
MVs are a paracrine factor, one advantage they have over
MSCs is the avoidance of possible long-term maldifferen-
tiation of engrafted cells or tumor generation. In addition,
in high concentrations under highly homogeneous prepar-
ation conditions, MVs provide focused stimulation that
allows for their interaction with target cells and, in turn,
positive reparative effects on damaged organs [12].
Erythropoietin (EPO) is a glycoprotein hormone that
stimulates the formation and differentiation of erythroid
precursor cells in bone marrow via the EPO receptor
(EpoR). An increasing amount of evidence has demon-
strated that other cell types, including neurons, endothe-
lial cells, cardiomyocytes, and renal tubular cells, also
express EpoR and respond to EPO treatment [13]; these
findings expand the potential biological roles of EPO
beyond erythropoiesis. The majority of in vivo and
in vitro experimental studies have shown that EPO pro-
tects against acute tissue injury in the brain, heart, and
kidney via the activation of relevant signaling pathways
that prevent apoptosis and/or stimulate reparative prolif-
eration in the cells of injured tissue [14–17].
Bone marrow-derived cells, both MSCs and endothe-
lial progenitor cells (EPCs), express EpoR and/or medi-
ate the proliferation of cells following EPO treatment
[18, 19]. Mice MSCs express EpoRs, and the in vitro
application of EPO to these cells prevents apoptotic cell
death, whereas its in vivo administration increases thenumber of MSCs in the bone marrow and spleen [13].
Based on these findings, we investigated the influence of
EPO on MVs derived from MSCs (EPO-MVs), and the
protective effects of these factors in an in vivo mouse
model of CKD. In addition, in vitro experiments were
conducted to assess the miRNA expression profile in
EPO-MVs that may be responsible for the enhanced
effectiveness of this paracrine factor in protecting renal
function. This expression was compared to the miRNA
expression of MSC-derived MVs (MSC-MVs).
Methods
Isolation of mMSC and incubation with EPO
The mice primary bone marrow mesenchymal stem
cells (BM-MSCs) were obtained from four-week-old
male C57BL/6 mice, cultured and characterized as previ-
ously described [20]. The extracted MSCs were cultured
to the P3 generation. Then, purified P3-mMSCs were
grown under different conditions on six-well culture
plates with 105 cells/well: group A (control group),
Dulbecco’s modified Eagle’s medium nutrient mixture
F-12 (DMEM/F12) with 10 % fetal bovine serum and 2 %
penicillin/streptomycin (Hyclone Labs, Logan, UT, USA);
group B (different concentrations of the EPO incubation
group): Dulbecco’s modified Eagle’s medium nutrient mix-
ture F-12 (DMEM/F12) with 10 % fetal bovine serum and
2 % penicillin/streptomycin (Hyclone Labs) plus different
concentrations of EPO (1, 10, 100 and 500 IU/ml for each
subgroup, respectively) (Gibco, Frederick, BRL Co. Ltd.,
MD, USA). Each group was incubated for two days. The
extracted cells of group A and group B were identified
according to their characteristic of osteogenesis and ad-
ipogenesis properties and were also detected using flow
cytometry.
Isolation of MVs and EPO-MVs
The culture medium of each group was collected each
time the medium was replaced and then stored at −80 °C
to be centrifuged together at 3,000 g for 20 minutes. The
free-cell debris supernatants were centrifuged at 100,000 g
(Beckman Coulter, Irvine, CA, USA, Optima L-90 K ultra-
centrifuge) for 1 h at 4 °C, washed in serum-free medium
199 (M199) containing N-2-hydroxyethylpiperazine-N-2-
ethanesulfonic acid (HEPES) 25 mM (Sigma-Aldrich
(Shanghai),SHANGHAI, CHINA), ultracentrifuged a second
time under the same conditions, and then resuspended
with M199. The protein content of MVs from the control
group and EPO incubation groups were quantified using
the Bradford method (Bio-Rad, Hercules, CA, USA).
The culture and experimental treatement of HK2
Human renal proximal tubular epithelial cells HK2
(American Type Culture Collection, Manassas, VA, USA)
were cultured in Medium 199 powder (Invitrogen,
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vine serum (Gibco, Burlington, Canada) and 2 % peni-
cillin/ streptomycin (Hyclone Labs). The cells were
seeded for 3–4 days at 37 °C in 95 % air–5 % CO2,
then trypsinized by 0.25 % trypsin-EDTA (Gibco BRL
Co. Ltd.). Cells were growth-arrested in serum-free
medium over night before use in experiments. The
cells used in this experiment were at passages 10–15.
HK2 cells were incubated with recombinant human trans-
forming growth factor-β1 (TGF-β1) (R&D, Minneapolis,
MN, USA) (6 ng/ml) for 48 h and 72 h to induce fibrosis
with MVs (30 μg) or EPO-MVs (30 μg) treatment.Flow cytometry
The Annexin V-FITC apoptosis detection kit (Invitro-
gen) was used to detect apoptotic cells according to the
manufacturer’s protocol. Briefly, cells were gently
washed with PBS and collected using trypsinization, dis-
aggregated to a single cell suspension and incubated
with 5 μl of Annexin V-FITC and 10 μl of a PI solution
for 15 minutes in the dark. The apoptotic cells were de-
tected using flow cytometry (BD, San Diego, CA, USA),
then quantified and the percentage of apoptotic cells
measured.Animal treatments and surgical methods
Animal welfare and experimental procedures were carried
out in accordance with the Guide for the Care and Use of
Laboratory Animals (Ministry of Science and Technology
of China, 2006), and were approved by the animal ethics
committee of Nanjing Medical University. Healthy specific
pathogen-free (SPF) purpose-bred domestic C57BL/6
mice (6-weeks-old, 15–23 g body weight) were obtained
from the Model Animal Research Center of Nanjing
University, Jiangsu, China. Animals had ad libitum access
to rodent diet and tap water. The mice were kept in cages
with a 12:12-h light–dark cycle, a temperature of 21 °C ±2
°C, and a humidity of 55 % ±5 %.
Mice assigned to the unilateral ureteral obstruction
(UUO) model were anesthetized by tiletamine/zolaze-
pam (VIRBAC Laboratories, Carros, France) and placed
on a heating pad to maintain their temperature at 37 °C.
Left ureters were ligated with silk (4/0). Amoxicillin was
given to the animals after surgery for three days. Sham
animals underwent the same procedure, except that the
ureter was not ligated. The animals were randomly di-
vided into four groups: sham group (n = 10), UUO
group (n = 10), UUO + MVs group (n = 10), and UUO
+ EPO-MVs group (n = 10). The mice were injected in
the tail vein with MVs or EPO-MVs (30 μg/mouse) one
day after surgery The four groups were killed at 7 days
and 14 days after UUO.Biochemical analysis
Blood and urine were collected before the mice were
killed and serum levels of urea nitrogen (BUN) and cre-
atinine (Scr), and urine levels of protein were examined
using a Beckman Analyser II (Beckman Instruments,
Inc., Fullerton, CA, USA).
Renal immunostaining and histological analysis
After the mice were killed, the kidneys were fixed in 4 %
neutral-buffered paraformaldehyde for histological as-
sessment, embedded in paraffin and cut at 3 μm-thick.
Then, the sections were dewaxed using standard sequen-
tial techniques before Masson’s trichrome (MT) and
hematoxylin-eosin (HE) staining. Damage was assessed
as in previous studies [20, 21]. The degree of tubular cell
damage was scored by a pathologist, in a single-blind
manner, using the numerical Histological Score of Kid-
ney (HSK): 0, no damage; 1, unicellular, patchy isolated
necrosis; 2, tubular necrosis less than 25 %; 3, tubular
necrosis between 25 % and 50 %; 4, more than 50 %
tubular necrosis and presence of infarcted tissue [22].
The sections previously prepared for immunohisto-
chemistry were incubated with primary antibody E-
cadherin (1: 800, Bioworld, Louis Park, MN, USA) and
α-SMA antibody (1 μg/ml, Abcam, Cambridge, MA,
USA) according to the manufacturers’ protocols. After
washing, the sections were incubated with secondary
antibody, anti-rabbit secondary antibody (Santa Cruz
Biotechnology, Dallas, Texas, USA) at a 1:5000 dilution.
Finally, sections were counterstained with Mayer’s
hematoxylin, dehydrated, and observed.
Western blotting
Protein was extracted from kidney tissue and cultured
cells. The protein concentration was determined using
the Bradford method. Then, 40 μg of the extracted pro-
tein was electrophoresed on 10 % SDS polyacrylamide
gels and transferred to nitrocellulose membranes (Milli-
pore, Bedford, MA, USA). After blocking for 2 h at 4 °C in
blocking buffer (10 % fat-free milk TBS with 0.1 %Tween
20), the membrane was incubated overnight with anti-E-
cadherin (1:800, Bio-world), anti-α-SMA (1 μg/ml, Abcam),
and anti-β-tubulin (1: 5000, Bio-world). The membrane
was washed and incubated for 2 h at 4 °C with conjugated
anti-rabbit secondary antibody. Detection was performed
using enhanced chemiluminescence (Thermo Scientific,
Frederick, MD, USA) and photography.
Reverse transcription and real-time polymerase chain
reaction (RT-PCR)
Total RNA was extracted from MVs and HK2 cells ac-
cording to the Trizol (Invitrogen) manufacturer’s protocol.
cDNA was synthesized using the Takara SYBR®Prime-
ScriptTM miRNA RT-PCR Kit and the PrimeScript RT
Fig. 1 BCA assay changes in the secretion levels of MV derived
from MSC after stimulation with different concentrations of EPO
for 48 h (n = 3 per group). *p < 0.01 versus 0 IU/ml EPO, #p < 0.01
versus 10 IU/ml EPO. BCA bicinchoninic acid EPO erythropoietin
MSC mesenchymal stem cells MV microvesicles
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Quantitative real-time PCR was performed using a
SYBR PrimeScript miRNA RT-PCR Kit and SYBR Pre-
mix Ex TaqII (Tli RNaseH Plus) (Takara) with the
intron-spanning primers on ABI-Prism-7500 Sequence
Detection System (Applied Biosystems, Frederick, MD,
USA). The sequences of the PCR primers of mRNA are:






MicroRNA profiling arrays of MV and EPO-MV
To study the differential miRNA expression in MV and
EPO-MV, we performed miRNA expression profiling of
the culture supernatant of MSC with or without EPO
incubation using the miRCURY LNA Array (v.18.0)
(Exiqon, Vedbaek, Denmark). RNA samples were labeled
with the Exiqon miRCURY Hy3/Hy5 power labeling kit
and hybridized on the miRCURY LNA Array (version
18.0) station. Scanning was performed with the Axon
GenePix 4000B microarray scanner. GenePix pro version
6.0 was used to read image raw intensity. Replicated miR-
NAs were averaged and miRNAs at intensities ≥ 30 in all
samples were chosen for calculating the normalization fac-
tor. Expressed data were normalized using the median
normalization. After normalization, differentially expressed
miRNAs were identified through fold change filtering. The
microarray data were deposited in the NCBI Gene Expres-
sion Omnibus (GEO) public repository and are accessible
under GEO Series accession number GSE68665.
Statistical analysis
Results from three independent experiments were
expressed as mean ± standard deviation (SD). Compari-
sons between groups were performed using one-way
analysis of variance (ANOVA) in SPSS 17.0. P values
< 0.05 were considered significant.
Results
The characterization of EPO-treated MSCs and MVs
MSCs were obtained from C57BL/6 mice, and grown in
adherent cultures in a plastic culture dish as previously
described [20]. All cells were passaged to three generations
prior to experimental use, and a subpopulation of secreted
MVs induced by the incubation of MSCs in EPO was used;
this subpopulation exhibited an optimal concentration of
100 IU EPO/106 MSCs (Fig. 1). Flow cytometry analysis
confirmed that the MSCs and EPO-treated MSCs were all
CD45-negative and positive in phenotypic markers CD90,
CD44, CD105 (Fig. 2a). Cytofluorimetric analyses also
showed that both the MSC-MVs and EPO-MVs presentedseveral adhesion molecules known to be expressed on
MSC plasma membrane, such as CD44, CD29 and
α4-integrin (Fig. 2b).
Marrow stromal cells are often referred to as MSCs
due to their ability to differentiate into mesenchymal cell
types [23]. This cellular feature distinguishes MSCs from
hematopoietic cells and other end-differentiated somatic
and progenitor cells that also reside in bone marrow. To
verify whether the mesenchymal differentiation capabil-
ity of the MSCs would change following incubation in
EPO, the EPO-treated MSCs were exposed in vitro to
specific agents that induce osteogenic or adipogenic
differentiation. As shown in Fig. 2c, following exposure
to β-glycerol phosphate, ascorbic acid 2-phosphate, and
dexamethasone, the undifferentiated cells developed an
osteogenic phenotype, whereas after exposure to insulin,
dexamethasone, 3-isobutyl-methylxanthine, and indo-
methacin, the cells manifested an adipogenic phenotype.MSC-MVs and EPO-MVs reversed TGF-β1-induced
morphological changes in HK2 cells
To assess the effects of transforming growth factor-β1
(TGF-β1) on cell morphology, HK2 cells were growth-
arrested in serum-free medium over night and then
treated with TGF-β1 (6 ng/ml) for 48 h or 72 h with or
without MSC-MVs or EPO-MVs. Phase-contrast micros-
copy revealed a decrease in cell-to-cell contacts, a more
elongated morphological shape of the cells following
TGF-β1 stimulation, and more severe fibrosis at 72 h
than at 48 h (Figs. 3c-d). Both types of MVs significantly
attenuated the TGF-β1-induced morphological changes,
but EPO-MVs had a superior effect (Figs. 3e-h).
Fig. 2 Analysis of the expression of surface markers and characterization of MSCs and EPO-MSC. a MSCs and EPO-MSC were labeled with the antibody
against CD45, CD105, CD90 and CD44, the cells present were positive for CD105, CD90 and CD44 but negative for CD45. b Representative FACS
analyses of MSC-MVs and EPO-MVs expressed similar results in CD44, CD29 and α4-integrin. c As described in Methods, MSC and EPO incubation
MSC(EPO-MSC) undifferentiated, when 50 to 60 or 70 to 80 % confluent, were cultured in conditions that were inducive of osteogenic or adipogenic
differentiation, respectively. After osteogenic differentiation, calcium in the mineralized extracellular matrix was shown by Alizarin Red S staining. After
adipogenic differentiation, lipid droplets were indicated by their staining with Oil Red O. EPO erythropoietin FACS fluorescence-activated cell sorting
MSC mesenchymal stem cells
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changes in the expression of E-cadherin and α-SMA in
HK2 cells
To confirm the transformation of the cells into a
fibroblast-like phenotype, the expression of E-cadherin
and α-smooth muscle actin (α-SMA) in HK2 cells was
examined using reverse transcription polymerase chain
reaction (RT-PCR) and Western blot analyses. The
stimulation of cells with TGF-β1 for 48 h significantly
reduced the mRNA levels of E-cadherin in HK2 cells
compared to controls; this effect was even larger at 72 h.
However, in the presence of MVs, the TGF-β1-induced
decrease in E-cadherin mRNA was restored, and the
cells exhibited an enhanced reparative ability. In con-
trast, the expression of α-SMA mRNA exhibited amarked time-dependent increase following stimulation
with TGF-β1 at 48 h and 72 h in HK2 cells compared to
the control. Both types of MVs reversed this increase,
but there was a superior effect with EPO-MVs (Fig. 4a).
The protein levels of E-cadherin and α-SMA, as re-
vealed by Western blot and RT-PCR analyses, showed
that both types of MVs restored the TGF-β1-induced
changes in E-cadherin and α-SMA in HK2 cells at 48 h
and 72 h. However, EPO-MVs exerted a greater repara-
tive influence than MSC-MVs (Fig. 4b).
MSC-MVs and EPO-MVs inhibited apoptosis in TGF-β1-
treated HK2 cells
To further investigate the anti-apoptotic roles of MSC-
MVs and EPO-MVs in HK2 cells following stimulation
Fig. 3 Representative micrographs from each experimental group. a-b The control group presented polygonal or oval cells, arranged regularly,
and showed the characteristics of cobblestone morphology in epithelial cells. c-d When TGF-β1 (6 ng/ml) was added to these groups to co-culture for
48 or 72 h, the cells lost connection, and the cobblestone morphology was replaced by hypertrophy and long spindle fibroblast-like morphology.
Floating cells were increased, and fibrosis injury was more pronounced at 72 h. e-h MVs/EPO-MVs could partly suppress the HK2 cell morphological
changes induced by TGF-β1. Most cells had normal morphology, the degree of fibrosis and its scope were appropriately reduced; in addition, the G-H
groups had less fibrosis than the E-F groups. EPO erythropoietin HK2 human kidney 2 MVs microvesicles TGF-β1 transforming growth factor-β1
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cultured with TGF-β1 in the HK2 cells for 48 h and 72
h. Flow cytometry analyses revealed that the TGF-β1-
induced apoptosis rate of HK2 cells was 9.86 % at 48 h,
but the independent application of MSC-MVs and EPO-
MVs reduced that rate to 5.27 % and 3.61 %, respect-
ively. At 72 h, the apoptosis rate increased to 10.9 %, but
the independent application of MSC-MVs and EPO-MVs
reduced that rate to 5.5 % and 2.9 %, respectively. These
findings indicate that both types of MVs, but especially
EPO-MVs, play an important anti-apoptotic role in HK2
cells treated with TGF-β1 (Fig. 5).
MSC-MVs and EPO-MVs protected against unilateral ur-
eteral obstruction (UUO)-induced CKD
All subjects in the experimental group survived, and the
body weight of each subject was recorded every 3 days
until the time of sacrifice. There were no significant dif-
ferences in body weight observed among the groups
(data not shown).
There were significant increases in serum creatinine
and blood urea nitrogen (BUN) levels on days 7 and 14
after the induction of UUO (Fig. 6a). These changes
were associated with considerable tubular epithelial in-
juries that were characterized by tubular dilation, apop-
tosis, and necrosis, the detachment of tubular epithelial
cells, and the presence of proteinaceous casts in the
tubules (Fig. 6b). However, there was a significant reduc-
tion of the tubular lesions in UUO mice injected with 30μg MSC-MVs or EPO-MVs 1 day after surgery com-
pared to UUO mice treated with vehicle. The tubular le-
sions in mice treated with EPO-MVs exhibited markedly
better improvement. UUO mice treated with MVs, espe-
cially EPO-MVs, also displayed significantly lower levels
of serum BUN and urine proteinuria (data not shown)
on days 7 and 14 compared to UUO mice treated with
vehicle (Fig. 6a).
An assessment of these changes was made using the
histological score of kidney (HSK). The kidneys of UUO
mice had a score of 2.85 ± 1.0 on day 7 and a score of
3.75 ± 0.5 on day 14, but treatment with both types of
MVs restored the morphology of the kidney. Treatment
with MSC-MVs resulted in a score of 1.75 ± 0.5 on day
7 and a score of 2.0 ± 0.57 on day 14, whereas treatment
with EPO-MVs resulted in a score of 1.17 ± 0.3 on day 7
and a score of 1.16 ± 0.6 on day 14. Each of these scores
was statistically significant compared to vehicle-treated
UUO subjects (p < 0.05).
Following the UUO procedure, Masson’s trichrome
staining revealed a time-dependent increase in extracel-
lular matrix depositions within the tubulointerstitium in
which the fibrosis was more severe on day 14. However,
both types of MVs resulted in a significant reduction of
extracellular matrix deposition in UUO mice, which was
greater in the kidneys of mice treated with EPO-MVs
(Fig. 6b). An immunohistochemical assessment of
α-SMA, a marker of myofibroblasts, demonstrated that
there was a time-dependent increase in α-SMA-positive
Fig. 4 The expression of E-cadherin and α-SMA in HK2 cells. a The analysis of gene expression of E-cadherin and a-SMA in HK2 cells following TGF-β1
(6 ng/ml) by RT-PCR at two time points (48 and 72 h) with MVs or EPO-MVs. All of the experiments were repeated three times (n = 3). b Western blot
was used to detect the protein expression of E-cadherin and α-SMA in HK2 cells following TGF-β1 (6 ng/ml) at two time points (48 and 72 h) with MVs
or EPO-MVs. All of the experiments were repeated three times (n = 3).*p < 0.01, 48-h TGF-β1 group versus HK-2 group or 72-h TGF-β1 group versus
HK-2 group, $p < 0.01, 48-h HK2 + TGF-β1 + MV group versus TGF-β1 group or 72-h HK2 + TGF-β1 + MV group versus TGF-β1 group, #p < 0.05, 48-h
HK2 + TGF-β1 + EPO-MV group versus HK2 + TGF-β1 + MV group or 72-h HK2 + TGF-β1 + EPO-MV group versus HK2 + TGF-β1 + MV. EPO erythropoietin
HK2 human kidney 2 MVs microvesicles TGF-β1 transforming growth factor-β1 α-SMA α-smooth muscle actin
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ure. However, the administration of both types of MVs,
especially EPO-MVs, resulted in a significant decrease in
the α-SMA-positive areas compared to UUO mice on
days 7 and 14. On the other hand, E-cadherin, a normal
epithelial marker, was markedly reduced in UUO mice.E-cadherin levels were preserved by administration of
both types of MVs, especially EPO-MVs (Fig. 6c).
Expression of α-SMA and E-cadherin in mice kidneys
The expression levels of α-SMA and E-cadherin were
determined by Western blot analyses. The expression
Fig. 5 MVs and EPO-MVs inhibited apoptosis of TGF-β treated HK2 cells. Representative photographs of annexinV/PI double-staining in different
groups and flow cytometry to test the HK2 cells apoptosis rate after culture in TGF-β1 (6 ng/ml) with MV or EPO-MV at two time points (48 and 72 h)
(n = 3 each group). MV and EPO-MV could reduce HK2 cell apoptosis induced by TGF-β1, EPO-MV did better. *p < 0.01, 48-h TGF-β1 group versus HK-2
group or 72-h TGF-β1 group versus HK-2 group, $p < 0.01, 48-h HK2 + TGF-β1 + MV group versus TGF-β1 group or 72-h HK2 + TGF-β1 + MV group
versus TGF-β1 group, #p < 0.05, 48-h HK2 + TGF-β1 + EPO-MV group versus HK2 + TGF-β1 + MV group or 72-h HK2 + TGF-β1 + EPO-MV group versus
HK2 + TGF-β1 + MV. EPO erythropoietin HK2 human kidney 2 MVs microvesicles PI propidium iodide TGF-β1 transforming growth factor-β1
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UUO mice compared to control mice on days 7 and 14,
and EPO-MVs were more effective than MSC-MVs in
restoring these levels. On the other hand, the expres-
sion of E-cadherin was lower in UUO mice on days 7
and 14, but EPO-MVs were also more effective than
MSC-MVs in restoring these levels (Fig. 7).Changes in the miRNA profiles of MSC-MVs and EPO-MVs
Scanned images of the MSC-MVs and EPO-MVs were
imported into GenePix Pro 6.0 software (Axon) for grid
alignment and data extraction. The replicated miRNAs
were averaged, and miRNAs with intensities ≥ 30 in all
samples were used to calculate the normalization factor.
The expressed data were normalized with median
Fig. 6 Effect of intravenous injection of MVs or EPO-MVs into unilateral ureteral obstruction (UUO) mice. a Mice were subjected to unilateral ureteral
obstruction on day 0, followed by intravenous injection of MVs or EPO-MV on day 1 (n = 5 each group). Creatinine and blood urea nitrogen values
were determined at the beginning of the experiments and on days 7 and 14 after surgery. *p < 0.01, day 7 UUO group versus control group or day 14
UUO group versus control group, $p < 0.01, day 7 UUO + MV group versus UUO group or day 14 UUO + MV group versus UUO group, #p < 0.05, day
7 UUO + EPO-MV group versus UUO + MV group or day 14 UUO + EPO-MV group versus UUO + MV group. b Representative micrographs of renal
histology of the kidney sections with hematoxylin and eosin (HE) and Masson’s trichrome (MT) at days 7 and 14 after surgery in control mice, in UUO
mice injected with 30 μg of MVs or EPO-MV. Magnification: ×200. c Immunohistochemistry of α-SMA and E-cadherin in renal histology of the kidney
sections at days 7 and 14 after surgery in control mice and in UUO mice with or without 30 μg MVs or EPO-MV. EPO erythropoietin MVs microvesicles
UUO unilateral ureteral obstruction α-SMA α-smooth muscle actin
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were identified using fold change filtering. Subsequently,
the miRNA profiles of the MSC-MVs and EPO-MVs
were analyzed with a quantitative PCR (qPCR)-based
array of the whole mice genome. Further analysis re-
vealed differences in the miRNAs of 212 EPO-MVs (fold
change ≥ 1.5 compared to the MSC-MVs), which consti-
tuted approximately 22.64 % of all the evaluated mouse
miRNAs. Of all the differences, 70.28 % of the changes
in the EPO-MV group involved upregulation (Fig. 8b);
this was greater than the changes in the MSC-MV group.
Discussion
In recent years, MSCs have received an increasing
amount of attention in the field of regenerative medicine
because they possess a number of potential therapeutic
applications for patients with acute and chronic tissueinjury in organs such as the heart, kidneys, lungs and
liver. In fact, MSCs are now used in clinical trials to
treat a wide range of diseases [24]. Although MSCs have
multiple differentiation potentialities and migrate to
injured sites following systemic administration, several
recent studies have indicated that the differentiation of
MSCs in the cells of injured tissues has little therapeutic
benefit [5, 25, 26]. In fact, a large amount of evidence
indicates that the therapeutic effects of MSCs are
dependent on their paracrine functions, which allow for
the secretion of soluble factors that repair damaged tis-
sues [27–29]. For example, MVs released from MSCs are
known to contribute to tissue repair in various animal
models of injury [11, 30, 31].
MVs are defined as a vesicle population that is a mix-
ture of exosomes and shedding vesicles that can be de-
tected both in vitro and in vivo. These factors are
Fig. 7 The expression of E-cadherin and α-SMA following UUO and MVs/EPO-MVs administration. Western blot analysis was used to detect the
protein expression of E-cadherin and a-SMA as a percentage of tubulin in mice exposed to control and MV/EPO-MV administration at 7 and 14
days. All of the experiments were repeated three times (n = 3). *p < 0.01, 7 day UUO group versus control group or 14 day UUO group versus
control group, $p < 0.01, 7 day UUO + MV group versus UUO group or 14 day UUO + MV group versus UUO group, #p < 0.05, 7 day UUO + EPO-MV
group versus UUO + MV group or 14 day UUO + EPO-MV group versus UUO + MV group. EPO erythropoietin MVs microvesicles UUO unilateral ureteral
obstruction α-SMA α-smooth muscle actin
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action with cells via specific receptor–ligand interac-
tions, and the transfer of surface receptors, proteins, and
bioactive lipids to target cells after internalization [12].
In addition, MVs contain selected mRNA and miRNA
profiles, and aid in the exchange of genetic information
between cells [32–34]. MSCs release a significant amount
of MVs with mRNA and selected patterns of mature miR-
NAs that protect against acute and chronic kidney disease
[10, 11, 20]. In contrast to MSCs, MVs transfer complex
and biologically active substances derived from MSCs to
injured cells that favor tissue regeneration [7]. The re-
peated administration of allogeneic MVs that are derived
from MSCs may not involve the immune response, as they
do not express histocompatibility antigens.
Along with stem cell-based therapy, EPO has recently
been evaluated for the treatment of tissue injury due to
its novel pharmacological effects, because in addition
to its recognized erythropoietic function, EPO may pro-
tect tissues against various types of damage [35]. EPOenhances regeneration of the tubular epithelium via its
anti-apoptotic and anti-inflammatory features [36],
prevents acute kidney injury (AKI), and improves postop-
erative renal function when administered in a preventive
fashion [37]. Several studies have reported that EPO en-
hances the ability of MSCs to treat renal and heart injuries
[38, 39]. Based on such findings, the present study investi-
gated the influence of MVs derived from EPO-treated
MSCs, and evaluated the renal protective function of this
type of MV following chronic injury both in vivo and
in vitro.
Recent studies have shown that EPO regulates the
formation of red blood cells and the proliferation of
EPCs [40], gastric epithelial cells [41], and other non-
hematopoietic cells that express EpoRs. Using the
Bicinchoninic acid (BCA) assay and Cell Counting Kit-
8 (CCK-8), we found that the level of MVs secreted from
MSCs increased in a significant and dose-dependent
manner when treated with EPO concentrations between
1–100 IU/ml (Fig. 1). However, light microscopy data
Fig. 8 (See legend on next page.)
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Fig. 8 Changes in miRNA profiles of microvesicles (MVs) and EPO treated microvesicles (EPO-MVs). a Expression of miRNA in MVs and EPO-MVs, and
mapping of hierarchical clustering of miRNA and heat map display of miRNA profiles. Columns represent individual samples, and each row represents
individual assayed miRNA. Green represents down-regulation of miRNAs, and red represents up-regulation of miRNAs. b Fold regulation of significant
miRNA in MVs versus EPO-MVs. Up-regulated miRNAs are denoted in red, downregulated miRNAs are green. c The relative miRNA change in MVs and
EPO-MVs. The miR-299a-3p, miR-302b-5p, miR-499 and miR-200c-3p were all up-regulated in EPO-MVs; the up-regulation of miR-499 and miR-200c-3p
was significant (p < 0.001, n = 3). d The bar plot shows the top ten enrichment score value of the significant enrichment pathway of the predicted
possible target genes of miR-299a-3p, miR-302b-5p, miR-499 and miR-200c-3p. e The plot shows top ten biologic functions from the predicted
possible target genes of miR-299a-3p, miR-302b-5p, miR-499 and miR-200c-3p, P-value cutoff (p < 0.05). EPO erythropoietin miRNA microRNA
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death of MSCs, and that there was a marked decrease
in the optical density (OD) of the group receiving this
dose of EPO (see Additional file 1). Based on these
findings, it appears that the significant and dose-
dependent EPO-induced increase in MVs can be attrib-
uted to the proliferation of MSCs.
Our findings demonstrate that, although both types
of MVs had a beneficial effect, the influence of EPO-
MVs was considerably stronger than those of MSC-
MVs. According to the blood and urine examinations
of UUO mice that received MVs 1 day after surgery,
the serum levels of BUN in UUO mice exhibited a
marked decrease following both MSC-MV (p < 0.01)
and EPO-MV (p < 0.01) administration, but there was a
stronger effect of EPO-MVs on days 7 and 14 (p < 0.05).
In addition, both types of MVs significantly reduced the
serum creatinine levels of UUO mice compared to
vehicle-treated UUO mice (p < 0.01), but the difference in
serum creatinine levels between the EPO-MV and MSC-
MV groups was not statistically significant. Similarly, both
types of MVs markedly reduced the elevated levels of pro-
teinuria in UUO mice on days 7 and 14, but EPO-MVs
had a stronger effect (data not shown).
The kidney sections of UUO mice treated with MVs
that were stained with hematoxylin and eosin or Mas-
son’s trichrome demonstrated a relatively preserved
cytoarchitecture, and a reduction of the histological
features of renal injury. However, the mice treated with
EPO-MVs displayed fewer interstitial lymphocyte infil-
trates, less tubular swelling, less necrosis, and lower
levels of interstitial collagen deposition over time.
These findings indicate that a higher number of E-
cadherin-positive and a lower number of α-SMA-
positive cells were detected in the renal tubules and
capillaries of mice treated with EPO-MVs compared to
mice treated with MSC-MVs. The in vitro experiments
further supported the beneficial effects of treatment
with MSC-MVs and EPO-MVs. Both types of MVs
reversed the TGF-β1-induced epithelial–mesenchymal
transition (EMT) in HK2 cells and inhibited the apoptosis
of TGF-β1-treated HK2 cells. Once again, EPO-MVs had
a stronger effect than MSC-MVs.A previous study from our group found that MVs
ameliorated the renal damage observed in five of six
nephrectomized mice and protected kidneys in the same
manner as MSCs [20]. These protective effects are likely
due to the MV-controlled shuttling of particular miR-
NAs during renal cell regeneration. This shuttling of fac-
tors has been observed both in vivo and in vitro in
association with MVs derived from EPCs that have been
subjected to a knockdown of Dicer, an intracellular en-
zyme essential for the production of miRNA [10]. In
addition, clinical and experimental studies have provided
data that support a critical role for miRNAs in renal
pathophysiology. In a mouse model of diabetic nephrop-
athy, inhibition of miR-21 improved kidney function and
alleviated the progression of renal injury [42], whereas
inhibition of renal miR-192 suppressed the expression of
fibrotic markers, such as collagen, TGF-β1, and fibronec-
tin in a mouse model of type I diabetes nephropathy [43].
To explain the improved reparative effects associated
with MVs observed in the present study, a miRCURY™
LNA Array was conducted to assess whether the incuba-
tion of cells in EPO changes the expression of miRNAs
in MVs. The present findings demonstrate that greater
numbers of miRNAs (70.28 %) were upregulated in
EPO-MVs. Several recent reports have described miRNA
functions and their role in anti-fibrosis. miR-302 de-
creases TGF-β1-induced EMT in renal HKC8 epithelial
cells and attenuates the TGF-β1-induced mesangial pro-
duction of fibronectin and thrombospondin [44]. In vitro
studies have demonstrated that members of the miRNA-
200 family inhibit the E-cadherin transcriptional repres-
sors ZEB1 and ZEB2, which are implicated in EMT [45].
miR-299 may delay or protect against replicative senes-
cence via improvements in the metabolic activity of
senesced cells, but it does not stimulate growth in the
remaining senescent cells [46]. miR-499 plays an
inhibitory role in the mitochondrial apoptosis pathway,
and protects against H2O2-induced injury in cardiomyo-
cytes [47]. Our findings also demonstrate that miR-299,
miR-499, miR-302, and miRNA-200 were upregulated in
EPO-MVs (Fig. 8c). Thus, it is likely that the changes in
these miRNAs in EPO-MVs contributed to the enhanced
inhibition of TGF-β1-induced EMT, decreased levels of
Wang et al. Stem Cell Research & Therapy  (2015) 6:100 Page 13 of 14apoptosis in the proximal tubular epithelial cells, and
improved renal function in UUO mice.
There were several limitations in the present study.
Therefore, further investigation regarding the role of up-
regulated miRNAs in EPO-MVs is required to gain a
better understanding of the mechanisms underlying
MSC-induced renal protection. Nevertheless, these find-
ings will help guide future research in this area.
Limitation
The MSCs were cultured in normal 10 % FBS, and then
the MSC-MVs and EPO-MVs were collected. The
process of isolating and collecting MSC-MVs and EPO-
MVs was the same, and, therefore, the influence of FBS
on MSC-MVs and EPO-MVs was not only similar, but
mitigated to some extent, which allowed for a compari-
son of their reparative effects on CKD.
Conclusions
Our findings suggest that there was a dose-dependent in-
crease in the level of EPO-MVs within the range of 1–100
IU/ml EPO, the EPO-MVs had a greater benefit in UUO
mice and had a better restorative effect following TGF-β1-
induced fibrosis in HK2 cells. The changed miRNA in
EPO-MVs may have contributed to their enhanced
protective effects following renal injury compared to
MSC-MVs. Our findings may help to develop new
therapeutic MVs to CKD caused by renal fibrosis in
further work.
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